- Home
- NTIP vs LTRN Comparison
NTIP vs LTRN Comparison
Compare NTIP & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTIP | LTRN |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 49.9M |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NTIP | LTRN |
|---|---|---|
| Price | $1.32 | $3.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 15.2K | ★ 59.0K |
| Earning Date | 02-27-2026 | 11-12-2025 |
| Dividend Yield | ★ 7.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $150,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.16 | $2.55 |
| 52 Week High | $1.90 | $6.12 |
Technical Indicators
Market Signals| Indicator | NTIP | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 48.63 |
| Support Level | $1.32 | $2.90 |
| Resistance Level | $1.42 | $3.56 |
| Average True Range (ATR) | 0.04 | 0.26 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 31.80 | 57.11 |
Price Performance
Historical ComparisonAbout NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.